Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL.
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F23%3A00132790" target="_blank" >RIV/00216224:14740/23:00132790 - isvavai.cz</a>
Result on the web
<a href="https://www.vjhemonc.com/video/onkdhuqybo8-transcription-factor-foxo1-mediates-cell-survival-during-bcr-inhibitor-therapy-in-cll/" target="_blank" >https://www.vjhemonc.com/video/onkdhuqybo8-transcription-factor-foxo1-mediates-cell-survival-during-bcr-inhibitor-therapy-in-cll/</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL.
Original language description
In this interview, Marek Mráz, PhD, Central European Institute of Technology, Brno, Czech Republic, outlines a study on resistance of chronic lymphocytic leukemia (CLL) to BCR inhibitor therapy through increased activity of the FoxO1-Rictor-pAkt axis. This highlights the potential of FoxO1 as a novel therapeutic target, with testing of a FoxO1 inhibitor in vitro showing its ability to kill CLL cells.This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů